𝔖 Bobbio Scriptorium
✦   LIBER   ✦

LOW-DOSE ORAL CHEMOTHERAPY FOR HORMONE-REFRACTORY PROSTATE CARCINOMA (HRPC). ESTRAMUSTINE PHOSPHATE VERSUS ESTRAMUSTINE PHOSPHATE AND ETOPOSIDE. A RANDOMISED PHASE II STUDY OF GSTU FOUNDATION

✍ Scribed by V. Serretta; G. Morgia; V. Altieri; A. Siragusa; M. Motta; F. Orestano; M. Napoli; G. De Grande; A. Galuffo; D. Melloni; C. Pavone; M. Pavone Macaluso; R. Allegro

Book ID
118647455
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
63 KB
Volume
5
Category
Article
ISSN
1569-9056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly paclitaxel, estramustine phosphat
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma : Results of a Minnie Pearl Cancer Research Network Phase II Trial
✍ Anthony A. Meluch; F. Anthony Greco; Lisa H. Morrissey; Eric L. Raefsky; Ronald 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone‐refractory prostate carcinoma. ## METHODS Patients with hormone‐refractory p